(286 days)
Not Found
Not Found
No
The device description details a standard ELISA assay and mentions an automated processor, but there is no indication of AI or ML being used for data analysis, interpretation, or any other function. The performance studies focus on traditional metrics like sensitivity, specificity, and precision, not AI/ML-specific metrics.
No
This device is an in vitro diagnostic test for the detection of antibodies to Epstein-Barr Virus, used as an aid in diagnosis, not for treatment or therapy.
Yes
The device aids in the diagnosis of infectious mononucleosis by detecting IgG antibodies to Epstein-Barr Virus, which is a diagnostic function.
No
The device description clearly outlines a physical ELISA kit with reagents, microwells, and a process involving incubation, washing, and spectrophotometric reading. While it mentions potential use with an automated processor (MAGO® Plus), the core device is a hardware-based assay kit, not software only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the device is for the "qualitative and semi-quantitative determination of IgG antibodies to Epstein-Barr Virus... in human serum by indirect enzyme immunoassay." This clearly indicates that the device is intended to be used in vitro (outside the body) to analyze a human sample (serum) for diagnostic purposes (aiding in the diagnosis of infectious mononucleosis).
- Device Description: The "Device Description" details an "enzyme-linked immunosorbent assay (ELISA)" which is a common in vitro diagnostic technique. It describes the process of analyzing a human serum sample in microwells.
- Performance Studies: The "Summary of Performance Studies" and "Key Metrics" sections discuss clinical sensitivity, specificity, and agreement, which are standard performance measures for in vitro diagnostic devices.
The information provided aligns perfectly with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
For the qualitative and semi-quantitative determination of IgG antibodies to Epstein-Barr Virus (recombinant) Viral Capsid Antigen (EBV-VCA IgG) in human serum by indirect enzyme immunoassay. The Is-EBV-VCA IgG Test Kit may be used in combination with other Epstein-Barr serologies (Viral Capsid Antigen (VCA) IgM , Epstein-Barr Nuclear Antigen-1 (EBNA-1) IgG and IgM, Early Antigen-Diffuse (EA-D) IgG and IgM and heterophile antibody as an aid in the diagnosis of infectious mononucleosis (IM). The evaluation of pared sera, to determine a significant increase in VCA IgG antibody titer, can also aid in the diagnosis of acute infection. These reagents can be used either manually or in conjunction with the MAGO® Plus Automated Processor.
Product codes (comma separated list FDA assigned to the subject device)
LSE
Device Description
The EBV-VCA IgG ELISA Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgG to Epstein Barr viral capsid antigen in human serum.
Recombinant VCA antigen is bound to microwells. Diluted patient sera. Cut-Off Calibrator and controls are placed in the microwells and incubated. Anti-VCA IgG antibodes, if present, will bind to the antigen forming, antigen-antibody complexes. Residual sample is eliminated by aspirating and washing. Conjugate (horseradish peroxidase-labeled anti-human IgG) is added and will bind to these complexes. Unbound conjugate is removed by aspiration and washing. Substrate is then added and incubated. In the presence of bound enzyme the substrate is converted to an end product. The absorbance of this end product can be read spectrophotometrically at 450 nm (reference 600-630 nm) and is directly proportional to the concentration of IgG antibodies to VCA present in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Frozen retrospective sera from one hundred and seventy-five patients were characterized using commercially available kits for VCA IgG, VCA IgM, EBNA IgG and heterophile antibodies. All 175 sera were then tested by an independent clinical commercial laboratory using the Is-I:IBV-VCA IgG Test Kit.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A. Clinical Sensitivity and Specificity Using Characterized Sera
Study type: Clinical Sensitivity and Specificity
Sample size: 175 sera
Key results:
Of the 102 past infection sera tested: 99 positive for anti-VCA lgG, 0 negative, 3 equivocal.
Of the 37 current (recent) infection samples tested: 28 positive, 5 negative, 6 equivocal.
Of the 34 seronegative sera tested: 30 negative, 2 positive, 2 equivocal.
Overall agreement of the Is-VCA IgG Test Kit compared to EBV serological status was 157/164 = 95.7%.
B. Precision
Study type: Precision study at three different sites (manufacturer, research & development laboratory, clinical commercial laboratory)
Sample size: Four positive and two negative sera, assayed ten times each in three different runs.
Key results: Presented in Table 3 (Site #1), Table 4 (Site #2), and Table 5 (Site #3) with Intra-Assay and Interassay Precision (MEAN INDEX and CV%).
C. Specificity with Potentially Cross-Reactive Sera
Study type: Cross-reactivity study
Sample size: Sixteen sera, non-reactive for IgG antibodies to VCA in the Is-EBV-VCA IgG Test Kit, tested by HA for IgG antibody to varicella zoster, cytomegalovirus and herpes simplex virus.
Key results:
15/15 anti-VZV IgG positive sera were non-reactive for anti-VCA IgG.
3/3 anti-CMV IgG positive sera were non-reactive for anti-VCA IgG.
3/3 anti-HSV positive sera were non-reactive for anti-VCA IgG.
This suggests no specific cross-reactivity with the Is-EBV-VCA IgG Test Kit from these analytes.
D. Correlation of Manual and MAGO Plus Results
Study type: Correlation study between manual and automated methods.
Sample size: 196 serum samples.
Key results: Good correlation with a Pearson Correlation Coefficient of 0.986. Scattergram and regression line provided in Figure 3.
E. MAGO Plus Precision
Study type: Precision study on the MAGO Plus Automated EIA Processor.
Sample size: Six sera assayed ten times each in three different runs.
Key results: Presented in Table 6 (Site #2) for Intra-Assay and Interassay Precision.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Relative Sensitivity: 100%
Relative Sensitivity (Current Infection): 84.8%
Relative Specificity (Seronegative): 93.8%
Agreement: 95.7%
Intra-assay Precision (Positive samples, all sites) Overall Manual- 1.56-9.30 MAGO Plus- 2.48-12.03
Interassay Precision (Positive samples, all sites) Overall Manual- 4.28-10.50 MAGO Plus- 6.99-9.21
No Cross-reactivity
Pearson Correlation Cocfficient: 0.986
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3235 Epstein-Barr virus serological reagents.
(a)
Identification. Epstein-Barr virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Epstein-Barr virus in serum. The identification aids in the diagnosis of Epstein-Barr virus infections and provides epidemiological information on diseases caused by these viruses. Epstein-Barr viruses are thought to cause infectious mononucleosis and have been associated with Burkitt's lymphoma (a tumor of the jaw in African children and young adults) and postnasal carcinoma (cancer).(b)
Classification. Class I (general controls).
0
3/4/99
K98/812
510k Summary of Safety and Effectiveness
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the quirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K981812
Applicant Information
| Date Prepared: | May 18, 1998 |
|---|---|
| Name: | Columbia Bioscience, Inc. |
| Address: | 8775 M Centre Park Drive, #559 |
| Columbia, MD 21045 |
| Contact Person: | Norman Jenkins |
|---|---|
| PhoneNumber. | 410-995-1278 |
| Fax Number. | 410-995-0508 |
්යා
Device Information:
| Trade Name: | EBV VCA IgG ELISA Kit |
|---|---|
| Common Name: | EBV Viral Capsid Antigen FIA Test |
| Classification Name: | Epstein Barr Virus Serological Reagent |
Equivalent Device Description:
Wampole VCA IgG ELISA
Wampole VCA IgG ELISA kit contains instructions and materials for the qualitative and semi-quantitative tection of IgG antibodies to EBV-VCA IgG in human serum by indirect ELISA
The EBV-VCA IgG ELISA Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgG to Epstein Barr viral capsid antigen in human serum.
Intended Use: For the qualitative and semi-quantitative determination of IgG antibodies to Epstein-Barr Virus (recombinant) Viral Capsid Antigen (EBV-VCA IgG) in human serum by indirect enzyme immunoassay. The Is-EBV-VCA IgG Test Kit may be used in combination with other Epstein-Barr serologies (Viral Capsid Antigen (VCA) IgM , Epstein-Barr Nuclear Antigen-1 (EBNA-1) IgG and IgM, Early Antigen-Diffuse (EA-D) IgG and IgM and heterophile antibody as an aid in the diagnosis of infectious mononucleosis (IM). The evaluation of pared sera, to determine a significant increase in VCA IgG antibody titer, can also aid in the diagnosis of acute infection. These reagents can be used either manually or in conjunction with the MAGO® Plus Automated Processor.
Principle of Procedure:
Recombinant VCA antigen is bound to microwells. Diluted patient sera. Cut-Off Calibrator and controls are placed in the microwells and incubated. Anti-VCA IgG antibodes, if present, will bind to the antigen forming, antigen-antibody complexes. Residual sample is eliminated by aspirating and washing. Conjugate (horseradish peroxidase-labeled anti-human IgG) is added and will bind to these complexes. Unbound conjugate is removed by aspiration and washing. Substrate is then added and incubated. In the presence of bound enzyme the substrate is converted to an end product. The absorbance of this end product can be read spectrophotometrically at 450
1
nm (reference 600-630 nm) and is directly proportional to the concentration of IgG antibodies to VCA present m the sample
ie Is-EBV-VCA IgG ELISA kit and the Wampole VCA IgG ELISA are substantially equivalent in that.
- Both are in vitro immunologic methods. 1.
- 2 Both are intended for use in the detection of IgG antibody to EBV-VCA in human serum
- 3 Both are based on the formation of a complex between VCA antigens and antibody
- 4 Both use antigen coated microtiter plates.
-
- Both are qualitative/semi-quantitative assays.
- రు. Both use goat anti-human IgG conjugated to horseradish peroxidase.
-
- Both use TMB as the enzyme substrate
A detailed comparison between the proposed devise and the predicate device is shown in Table 1
Conclusions: The Diamedix Is-EBV-VCA IgG is substantially equivalent to the Wampole VCA ELISA for the detection of IgG antibodies to EBV-VCA in human serum to aid in the diagnosis of infectious mononucleosis The device is as safe, as effective, and performs as well as the legally marketed device described.
2
1883678
PREDICATE DEVICE
POOls FRV-VC A løG FI ...
| Table 1 | ||
|---|---|---|
| PROPOSED DEVICE | ||
| Diamedix Is-EBV-VCA IgG ELISA Kit | PREDICATE DEVICE | |
| Wampole EBV-VCA IgG ELISA | ||
| Ended Use | For the qualitative and semi-quantitative determination of | |
| IgG antibodies to Epstein-Barr Virus Viral Capsid | ||
| Antigen (EBV-VCA IgG) in human serum by indirect | ||
| enzyme immunoassay. The Is-EBV-VCA IgG Test Kit | ||
| may be used in combination with other Epstein-Barr | ||
| serologies (Viral Capsid Antigen (VCA) IgM, Epstein- | ||
| Barr Nuclear Antigen-1 (EBNA-1) IgM, Early Antigen- | ||
| Diffuse (EA-D) IgG and IgM and heterophile antibody as | ||
| an aid in the diagnosis of infectious mononucleosis (IM). | ||
| The evaluation of paired sera, to determine a significant | ||
| increase in VCA IgG antibody titer, can also aid in the | ||
| diagnosis of acute infection. These reagents can be used | ||
| either manually or in conjunction with the MAGO® Plus | ||
| Automated Processor. | The Wampole Laboratories (Wampole) Epstein-Barr | |
| Virus-Viral Capsid IgG Enzyme-Linked ImmunoSorbent | ||
| Assay (ELISA) is intended for the qualitative and semi- | ||
| quantitative determination of IgG antibody in human | ||
| serum to Epstein-Barr virus in human sera. A single | ||
| serum specimen may be used to indicate previous | ||
| infection or immune status with the Epstein-Barr virus | ||
| Paired sera, acute and convalescent, may be used to | ||
| demonstrate seroconversion or a significant rise in | ||
| antibody level as an aid in the diagnosis of a recent or | ||
| current infection, or reactivation; and as an aid in the | ||
| diagnosis of Infections Mononucleosis (IM). | ||
| Methodology | Enzyme immunoassay (EIA) | Enzyme Linked Immunosorbent Assay (ELISA) |
| Specifications | For in vitro diagnostic use. | |
| For use with fresh or frozen human serum. | ||
| Avoid lipemic, hemolyzed, contaminated, or icteric sera. | ||
| Assay performed on 1:21 dilution of serum at 18-30°C. | ||
| Store at 2-8°C. | For in vitro diagnostic use. For use with fresh or frozen | |
| human serum. Assay performed on 1:21 dilution of | ||
| serum at 21-25°C. Store at 2-8°C. | ||
| Design | Is-EBV-VCA IgG Test Kit. 96 determinations. Un- | |
| diluted Calibrator, Positive, and Negative controls. | VCA IgG ELISA. 96 determinations. Undiluted | |
| Calibrator, High positive, Low positive, and Negative | ||
| controls. | ||
| Principles of | ||
| Operation | Purified, recombinant VCA antigen is bound to | |
| microwells (solid phase). Diluted human serum is added | ||
| to the microwell which binds human anti-VCA IgG, if | ||
| present. Solid phase is washed and exposed to anti- | ||
| human IgG conjugate. Solid phase is washed and | ||
| exposed to enzyme substrate to develop color. Strong | ||
| acid is added to stop reaction. The color is read at | ||
| 450/600 nm on an EIA reader. | Diluted patient serum is incubated with purified, VCA | |
| antigen bound to the solid surface of a microtiter well. If | ||
| IgG antibodies against EBV-VCA are present in the | ||
| serum, antigen-antibody complexes are formed. These | ||
| complexes bind with HRP-labeled anti-human IgG which | ||
| react with the addition of chromogen, resulting in a color | ||
| development. The absorbance is measured at 450/630 | ||
| nm. | ||
| Performance | ||
| Characteristics | Relative Sensitivity: 100% | |
| Relative Sensitivity (Current Infection): 84.8% Relative | ||
| Specificity (Seronegative): 93.8% | ||
| Agreement: 95.7% | ||
| Intra-assay Precision (Positive samples, all sites) | ||
| Overall Manual- 1.56-9.30 MAGO Plus- 2.48-12.03 | ||
| Interassay Precision (Positive samples, all sites) | ||
| Overall Manual- 4.28-10.50 MAGO Plus- 6.99-9.21 | ||
| No Cross-reactivity | Relative Sensitivity: 100% | |
| Relative Specificity: 100% | ||
| Agreement: 100% | ||
| Inter-Site Precision (Positive samples, all sites) | ||
| Overall: 1.9-9.6% | ||
| No Cross-reactivity | ||
| Enzyme Used | Horseradish Peroxidase | Horseradish Peroxidase |
| Substrate | TMB | TMB |
| Specimen | Serum | Serum |
| Calculation of Results | Sample Absorbance/Cut-off Absorbance = Index Value | Sample Absorbance/Cut-off Absorbance = ISR |
| Interpretation | 1.10 Positive for VCA IgG | 1.10 Positive for VCA IgG |
| Materials | 96 microwells in 12x8 strips, Wash concentrate, Sample | |
| Diluent, Conjugate, Calibrator, Controls, Substrate, Stop | ||
| Solution | 96 microwells in 12x8 strips, Wash Buffer, Serum | |
| Diluent, HRP Conjugate, Calibrator, Controls. | ||
| Chromogen, Stop Solution |
Table 1
3
Performance Characteristics
Is-IEBV-VCA I
A. Clinical Sensitivity and Specificity Using Characterized Sera
Frozen retrospective sera from one hundred and seventy-five patients were characterized using commercially available kits for VCA IgG, VCA IgM, EBNA IgG and heterophile antibodies, Based on the results of this testing, the patient sera were characterized as follows :
- · 102 sera were characterized as convalescent (past infection). These were positive for VCA IgG and or EBNA IgG antibodies and negative for VCA IgM and heterophile antibody.
- · 34 sera were characterized as seronegative. These were negative for VCA IgG. VCA IgM, EBNA IgG and heterophile antibody.
- · 39 sera were characterized as having a current (recent) intection. These were positive for VCA IgM and/or heterophile antibody and were negative for EBNA IgG.
All 175 sera were then tested by an independent clinical commercial laboratory using the Is-I:IBV-VCA IgG Test Kit. The results obtained are shown in Table 2:
| TABLE 2 | Convalescent | Current Infection | Seronegative | |
|---|---|---|---|---|
| IgG | POSITIVE | 99 | 28 | 2 |
| NEGATIVE | 0 | 5 | 30 | |
| EQUIVOCAL | 3 | 6 | 2 |
EBV Serological Status
- · Of the 102 past infection sera tested, 99 were positive for anti-VCA 1gG, none were negative, and 3 were equivocal.
- · Of the thirty-seven current (recent) infection samples lested, twenty-eight were positive, five were negative, and 6 were equivocal
- · Of the thirty-four seronegative sera tested, thirty were negative, two were possitive, and two were equivocal.
- · The overall agreement of the Is-VCA IgG Test Kit compared to EBV serological status was 157/164 = 95.7%:
4
B. Precision
To determine the precision of the Is-FINV-VCA IgG Test Kit, four positive and two negative sera were assayed ten times each in three different runs at three different sites included: the manufacturer, a research & development laboratory, and a clinical commercial laboratory. The intrassay precision obtained at each site is shown in Tables 3, 4 and 5.
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN | ||||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | |||||||
| A (POS) | 1.74 | 3.19 | 1.98 | 6.84 | 1.64 | 7.16 | 1.79 | 10.13 |
| B (POS) | 2.05 | 5.34 | 2.42 | 4.11 | 1.98 | 6.56 | 2.15 | 10.50 |
| C (POS) | 1.42 | 4.56 | 1.55 | 9.30 | 1.48 | 9.05 | 1.48 | 8.63 |
| D (POS) | 3.12 | 4.38 | 3.31 | 4.49 | 3.07 | 4.17 | 3.17 | 5.40 |
| E (NEG) | 0.54 | 16.22 | 0.58 | 11.87 | 0.54 | 11.17 | 0.55 | 13.30 |
| F (NEG) | 0.21 | 16.31 | 0.25 | 21.86 | 0.21 | 12.12 | 0.22 | 19.06 |
| CAL | 1.04 | 13.48 | ||||||
| PC | 1.75 | 15.91 | ||||||
| NC | 0.12 | 0.00 |
TABLE 3 : Site #1 - Intra-Assay and Interassay Precision
| TABLE 4 : Site #2- Intra-Assay and Interassay Precision | ||||
|---|---|---|---|---|
| -- | --------------------------------------------------------- | -- | -- | -- |
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN | ||||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | |||||||
| A (POS) | 1.59 | 4.45 | 1.52 | 3.20 | 1.67 | 3.23 | 1.60 | 5.31 |
| B (POS) | 1.96 | 3.41 | 1.87 | 2.14 | 2.04 | 3.45 | 1.96 | 4.71 |
| C (POS) | 1.54 | 3.86 | 1.33 | 3.43 | 1.52 | 1.56 | 1.46 | 7.10 |
| D (POS) | 3.27 | 2.40 | 2.90 | 1.86 | 3.23 | 2.74 | 3.13 | 5.91 |
| E (NEG) | 0.55 | 5.11 | 0.55 | 2.29 | 0.64 | 3.76 | 0.58 | 8.22 |
| F (NEG) | 0.231 | 3.36 | 0.25 | 4.86 | 0.28 | 9.96 | 0.25 | 10.66 |
| CAL | 1.00 | 1.80 | ||||||
| PC | 1.47 | 4.24 | ||||||
| NC | 0.16 | 6.13 |
TABLE 5 : Site #3 - Intra-assay and Interassay Precision
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN | CV% | MEAN | CV% | MEAN | CV% | MEAN | CV% | |
| INDEX | INDEX | INDEX | INDEX | |||||
| A (POS) | 1.59 | 3.51 | 1.56 | 5.21 | 1.52 | 3.00 | 1.55 | 4.37 |
| B (POS) | 1.91 | 4.17 | 1.89 | 4.58 | 1.85 | 6.07 | 1.88 | 5.04 |
| C (POS) | 1.44 | 4.60 | 1.36 | 3.53 | 1.37 | 3.26 | 1.39 | 4.61 |
| D (POS) | 3.05 | 4.38 | 3.02 | 3.43 | 2.91 | 3.88 | 2.99 | 4.28 |
| E (NEG) | 0.55 | 6.77 | 0.60 | 7.37 | 0.54 | 5.08 | 0.56 | 8.25 |
| F (NEG) | 0.28 | 8.78 | 0.36 | 64.52 | 0.27 | 15.22 | 0.30 | 46.46 |
| CAL | 1.00 | 3.87 | ||||||
| PC | 1.33 | 16.45 | ||||||
| NC | 0.20 | 28.00 |
C. Specificity with Potentially Cross-Reactive Sera
Sixtcen sera, non-reactive (negative) for IeG antibodies to VCA in the Is-EBV-VCA IgG Test Kit, were ested by HA for IgG antibody to varicella zoster, cylomegalovirus and herpes simplex virus. 15/15 anti-VZV IgG positive sera were non-reactive for anti-YCA IgG; 3/3 mi-CMV IgG possible sera were non-reactive for anti-VCA IgG and 3/3 anti-HSV positive sera were non-reactive for anti-VCA IgG. This suggests that no specific cross-reactivity should by expected with the Is-EBV-VCA IgG Test Kit from these analytes.
D. Correlation of Manual and MAGO Plus Results
The Is-FINV-VCA IgG Test Kit has been developed for automated as well as manual use. To demonstrate the equivalence of the manual and MAGO Plus procedures, the results of 196 serum samples tested by both methods were plotted. A scattergram and regression line of the results obtained with 95% confidence intervals is shown in Figure 3 The data indicate good correlation with a Pearson Correlation Cocfficient of 0.986.
5
JUN
Image /page/5/Figure/3 description: This image is a scatter plot that shows the relationship between manual index values and MAGO plus index values. The x-axis represents the manual index values, and the y-axis represents the MAGO plus index values. The plot includes a regression line with the equation Y = -0.1151 + 1.2556X, and the correlation coefficient (r) is 0.9860, indicating a strong positive correlation between the two variables.
FIGURE 3 : Manual and MAGO Plus Result Correlation
D. MAGO Plus Precision
The precision of the assay when performed on the MAGO Plus Automated E1A Processor was determined by assaying six sera ten times cach in three different runs. Table 6 shows the intra-and interassay precision obtained using the MAGO Plus.
| TABLE 6 : Site #2- Intra-Assay and Interassay Precision - MAGO Plus |
|---|
| --------------------------------------------------------------------- |
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN INDEX | CV% | MEAN INDEX | CV% | MEAN INDEX | CV% | MEAN INDEX | CV% | |
| A (POS) | 1.68 | 3.76 | 1.52 | 4.16 | 1.67 | 7.50 | 1.62 | 6.99 |
| B (POS) | 2.15 | 5.48 | 1.89 | 4.63 | 2.07 | 4.58 | 2.04 | 7.23 |
| C (POS) | 1.63 | 2.96 | 1.44 | 5.86 | 1.49 | 12.03 | 1.52 | 9.21 |
| D (POS) | 3.57 | 3.75 | 3.06 | 3.51 | 3.18 | 2.48 | 3.27 | 7.50 |
| E (NEG) | 0.60 | 0.00 | 0.52 | 8.11 | 0.51 | 11.13 | 0.54 | 10.46 |
| F (NEG) | 0.30 | 15.71 | 0.25 | 21.08 | 0.21 | 15.06 | 0.25 | 22.55 |
| CAL | 1.00 | 5.54 | ||||||
| PC | 1.43 | 4.03 | ||||||
| NC | 0.20 | 0.00 |
6
Image /page/6/Picture/1 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features the department's name in a circular arrangement around an emblem. The emblem is a stylized image of an eagle or bird-like figure with three overlapping wing-like shapes.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAR - 4 1999
Diamedix Corp. c/o Norman Jenkins President Columbia Bioscience, Inc. 8775 M Centre Park Drive, #559 Columbia, MD 21045
Re: K981812
Trade Name: EBV-VCA IgG ELISA Test System Regulatory Class: I Product Code: LSE Dated: December 8, 1998 Received: December 9, 1998
Dear Mr. Jenkins:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
7
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
8
510(k) Number: K981812
Device Name: EBV- VCA IgG ELISA
Indications For Use: For the qualitative and semi-quantitative determination of IgG antibodies to Epstein-Barr Virus (recombinant) Viral Capsid Antigen (EBV-VCA IgG) in human serum by indirect enzyme immunoassay. The Is-EBV-VCA IgG Test Kit may be used in combination with other Epstein-Barr serologies (Viral Capsid Antigen (VCA) IgM , Epstein-Barr Nuclear Antigen-1 (EBNA-1) IgG and IgM, Early Antigen-Diffuse (EA-D) IgG and IgM and heterophile antibody as an aid in the diagnosis of infectious mononucleosis (IM). The evaluation of paired sera, to determine a significant increase in VCA IgG antibody titer, can also aid in the diagnosis of acute infection. These reagents can be used either manually or in conjunction with the MAGO® Plus Automated Processor.
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The Counter Use (Optional Format 1-2-96)
Woodley Dubois
() Number